Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2009 Jul 7;8(7):1878–1884. doi: 10.1158/1535-7163.MCT-09-0016

Figure 1.

Figure 1

Top1 levels decrease in a dose-dependent manner in topotecan-treated A375 cells. Cells were treated with 0.1 to 100 μM topotecan for 40, 75, or 165 minutes. Data are expressed relative to vehicle control (water).